Jaguar8 commented on a stock · Nov 12 20:31

NEWS ER

ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting

Positive
FDA confirmation that PROACT 1 Phase 3 study could be sufficient for full regulatory approval

Accelerated approval pathway available with eGFR slope as surrogate endpoint

Strong cash position of $406.8 million, supporting operations into 2027

Reduced R&D expenses by $0.9 million year-over-year

Slight improvement in net loss to $41.1 million from $42.0 million YoY

Negative
Increased G&A expenses by $3.3 million year-over-year

$5.3 million non-cash impairment charge related to Greensboro facility

Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more

Translate

Report

3337 Views

Comment

Spread kindness and love. Life is short. Don’t let greed eat you.

4202Followers

73Following

47KVisitors